TARS Tarsus Pharmaceuticals, Inc.

NASDAQ
$79.31

Tarsus Pharmaceuticals, Inc. (TARS) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

30D 90D 6M 1Y
Insider signal Moderately bearish Selling ran elevated versus TARS's own trailing one-year pace, with 42% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 6 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
9
38 transactions
Purchases
$0
0 shares
Sales
$12.3M
175,127 shares
Net activity
-$12.3M
purchases less sales

How much of that selling was preplanned? 42% planned / 58% discretionary

10b5-1 plan sales $5.1M 16 transactions · 69,460 shares
Discretionary sales $7.1M 22 transactions · 105,667 shares

Largest single sale: $877.4K.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Lin Elizabeth Yeu 4 fills Chief Medical Officer Sell 10b5-1 13,953 $87.50 $1.2M 7,933 −63.8% of holding
Azamian Bobak R. 2 fills President/CEO and Board Chair Sell 10b5-1 10,000 $90.56 $905.6K 830,891 −1.2% of holding
Neervannan Seshadri Chief Operating Officer Sell 10b5-1 4,564 $85.00 $387.9K 78,532 −5.5% of holding
Azamian Bobak R. 2 fills President/CEO and Board Chair Sell 10b5-1 10,000 $61.55 $615.5K 853,409 −1.2% of holding
Farrow Jeffrey S See Remarks Sell 14,396 $60.95 $877.4K 56,801 −20.2% of holding
LINK WILLIAM J PHD 2 fills Director Sell 10b5-1 12,500 $62.12 $776.5K 108,714 −10.3% of holding
Goodrich Katherine Director Sell 10b5-1 2,954 $62.08 $183.4K 2,233 −57% of holding
Neervannan Seshadri Chief Operating Officer Sell 10b5-1 2,989 $66.75 $199.5K 82,791 −3.5% of holding
Azamian Bobak R. President/CEO and Board Chair Sell 11,964 $67.00 $801.6K 33,421 −26.4% of holding
Neervannan Seshadri Chief Operating Officer Sell 4,589 $67.00 $307.5K 85,780 −5.1% of holding
Mottiwala Aziz Chief Commercial Officer Sell 4,440 $67.00 $297.5K 61,480 −6.7% of holding
Wahl Bryan General Counsel Sell 4,231 $67.00 $283.5K 63,959 −6.2% of holding
Whitfield Dianne C. Chief Human Resources Officer Sell 4,174 $67.00 $279.7K 35,028 −10.6% of holding
Farrow Jeffrey S See Remarks Sell 2,186 $67.00 $146.5K 43,316 −4.8% of holding
Lin Elizabeth Yeu Chief Medical Officer Sell 390 $67.00 $26.1K 23,308 −1.6% of holding
Azamian Bobak R. President/CEO and Board Chair Sell 11,667 $68.71 $801.6K 45,385 −20.4% of holding
Mottiwala Aziz Chief Commercial Officer Sell 4,330 $68.71 $297.5K 65,920 −6.2% of holding
Wahl Bryan General Counsel Sell 4,125 $68.71 $283.4K 68,190 −5.7% of holding
Whitfield Dianne C. Chief Human Resources Officer Sell 4,071 $68.71 $279.7K 39,202 −9.4% of holding
Neervannan Seshadri Chief Operating Officer Sell 3,610 $68.71 $248.0K 90,369 −3.8% of holding
Farrow Jeffrey S See Remarks Sell 2,133 $68.71 $146.6K 45,502 −4.5% of holding
Lin Elizabeth Yeu Chief Medical Officer Sell 379 $68.71 $26.0K 23,698 −1.6% of holding
Azamian Bobak R. President/CEO and Board Chair Sell 10,972 $69.42 $761.7K 57,052 −16.1% of holding
Mottiwala Aziz Chief Commercial Officer Sell 4,286 $69.42 $297.5K 70,250 −5.8% of holding
Wahl Bryan General Counsel Sell 4,084 $69.42 $283.5K 72,315 −5.3% of holding
Whitfield Dianne C. Chief Human Resources Officer Sell 4,029 $69.42 $279.7K 43,273 −8.5% of holding
Neervannan Seshadri Chief Operating Officer Sell 3,125 $69.42 $216.9K 93,979 −3.2% of holding
Farrow Jeffrey S See Remarks Sell 2,111 $69.42 $146.5K 47,635 −4.2% of holding
Lin Elizabeth Yeu Chief Medical Officer Sell 375 $69.42 $26.0K 24,077 −1.5% of holding
LINK WILLIAM J PHD 3 fills Director Sell 10b5-1 12,500 $68.79 $859.8K 125,203 −9.1% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.